These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31495833)

  • 1. Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy.
    Zhao G; Liu A; Zhang Y; Zuo ZQ; Cao ZT; Zhang HB; Xu CF; Wang J
    Biomater Sci; 2019 Nov; 7(11):4698-4707. PubMed ID: 31495833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
    Ghoshdastidar K; Patel H; Bhayani H; Patel A; Thakkar K; Patel D; Sharma M; Singh J; Mohapatra J; Chatterjee A; Patel D; Bahekar R; Sharma R; Gupta L; Patel N; Giri P; Srinivas NR; Jain M; Bandyopadhyay D; Patel PR; Desai RC
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00565. PubMed ID: 32790160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
    Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
    Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis.
    Liu YT; Ding HH; Lin ZM; Wang Q; Chen L; Liu SS; Yang XQ; Zhu FH; Huang YT; Cao SQ; Yang FM; Song ZL; Ding J; Geng MY; Xie H; Zhang A; He SJ; Zuo JP
    Acta Pharmacol Sin; 2021 Oct; 42(10):1653-1664. PubMed ID: 33441995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
    Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Whang JA; Chang BY
    Drug Discov Today; 2014 Aug; 19(8):1200-4. PubMed ID: 24721226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effect of Bruton's tyrosine kinase and TNF-α in the regulation of rheumatoid arthritis and underlying mechanisms.
    Du J
    Exp Ther Med; 2022 Feb; 23(2):141. PubMed ID: 35069822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
    Keaney J; Gasser J; Gillet G; Scholz D; Kadiu I
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):448-461. PubMed ID: 30758770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
    Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
    Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
    Kawahata W; Asami T; Kiyoi T; Irie T; Taniguchi H; Asamitsu Y; Inoue T; Miyake T; Sawa M
    J Med Chem; 2018 Oct; 61(19):8917-8933. PubMed ID: 30216722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
    Yao X; Sun X; Jin S; Yang L; Xu H; Rao Y
    J Med Chem; 2019 Jul; 62(14):6561-6574. PubMed ID: 31260299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
    Pery N; Rizvi NB; Shafiq MI
    J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
    Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
    Di Paolo JA; Huang T; Balazs M; Barbosa J; Barck KH; Bravo BJ; Carano RA; Darrow J; Davies DR; DeForge LE; Diehl L; Ferrando R; Gallion SL; Giannetti AM; Gribling P; Hurez V; Hymowitz SG; Jones R; Kropf JE; Lee WP; Maciejewski PM; Mitchell SA; Rong H; Staker BL; Whitney JA; Yeh S; Young WB; Yu C; Zhang J; Reif K; Currie KS
    Nat Chem Biol; 2011 Jan; 7(1):41-50. PubMed ID: 21113169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Bruton's tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis.
    Akasaka D; Iguchi S; Kaneko R; Yoshiga Y; Kajiwara D; Nakachi Y; Noma N; Tanaka K; Shimizu A; Hosoi F
    PLoS One; 2023; 18(2):e0282117. PubMed ID: 36821545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
    Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.